L-Arginine Supplements in Treating Women Who Are Cancer Survivors

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Wake Forest Cancer Center CCOP Research Base
ClinicalTrials.gov Identifier:
NCT00459134
First received: April 9, 2007
Last updated: March 15, 2013
Last verified: March 2013

April 9, 2007
March 15, 2013
May 2007
March 2010   (final data collection date for primary outcome measure)
Determine whether ArginMax improves the quality of life and sexual function. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Determine whether ArginMax improves the quality of life and sexual function for women cancer survivors by using the FACT-G and FSFI instruments.
Sexual function at 12 weeks
Complete list of historical versions of study NCT00459134 on ClinicalTrials.gov Archive Site
Quality of life [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Assess differences in quality of life between the two groups.
  • Determine differences in toxicity between the two groups.
  • Describe the sexual function symptom clusters (if any) in women cancer survivors.
  • To assess the effect of race on sexual function and quality of life.
  • Quality of life
  • Toxicity
Not Provided
Not Provided
 
L-Arginine Supplements in Treating Women Who Are Cancer Survivors
A Randomized Study to Determine Whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors

RATIONALE: L-arginine supplements may improve the quality of life and sexual function in women who are cancer survivors.

PURPOSE: This randomized clinical trial is studying an L-arginine supplement to see how well it works compared with a placebo in treating women who are cancer survivors.

OBJECTIVES:

Primary

  • Determine whether an L-arginine-based nutritional supplement (ArginMax®) improves the quality of life and sexual function in female cancer survivors.

Secondary

  • Compare quality of life of patients treated with ArginMax® vs placebo.
  • Compare toxicity of these regimens in these patients.
  • Describe the sexual function symptom clusters (if any) in these patients.

OUTLINE: This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Patients are stratified according to ECOG performance status (0 or 1 vs 2 or 3), type of malignancy (pelvic vs nonpelvic), and ovarian functional status (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive an oral L-arginine-based nutritional supplement (ArginMax®) twice daily.
  • Arm II: Patients receive oral placebo twice daily. In both arms, treatment continues for 12 weeks in the absence of unacceptable toxicity.

Sexual function, quality of life, and toxicity are assessed at baseline and every 4 weeks for 12 weeks.

PROJECTED ACCRUAL: A total of 186 patients will be accrued for this study.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Supportive Care
  • Sexual Dysfunction
  • Sexuality and Reproductive Issues
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Dietary Supplement: ArginMax
    Given orally
    Other Name: L-arginine
  • Dietary Supplement: placebo
    Given orally
  • Experimental: Arm I: ArginMax
    ArginMax® (including placebo)
    Intervention: Dietary Supplement: ArginMax
  • Placebo Comparator: Arm II
    Patients receive oral placebo twice daily
    Intervention: Dietary Supplement: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
186
March 2010
March 2010   (final data collection date for primary outcome measure)

INCLUSION CRITERIA:

Any female cancer survivor who identifies herself as concerned with her sexual quality of life and answering yes to all three of the screening questions.

  • Must express interest in sexual activity
  • At least 6 months following completion of all cancer therapy. Hormonal therapy and treatment with Herceptin are allowed.
  • No evidence of active cancer based on physical exam and/or radiographic images obtained within 3 months of study.
  • Absence of any mental, medical or physical disorder know to affect sexual function.
  • No participation in another study with an investigational study drug or device during the 30 days prior to start of study drug.
  • Lab values must meet the following criteria at study entry: WBC ≥ 2000, Hgb ≥ 10gm/dl, creatinine ≤ 1.5 x ULN, plt ≥ 100,000, T Bili ≤ 1.5
  • ECOG performance status must be 0-2.
  • Must be able to take oral medication
  • Must be 18 years old or older
  • Must be minority (non-white) female.

EXCLUSION CRITERIA:

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ArginMax.
  • Currently taking any blood thinner such as aspirin (one 81mg aspirin, or one baby aspirin per day allowed), Persantine, Heparin, Lovenox, or Coumadin (low dose Coumadin for catheter patency is allowed).
  • Patients currently taking Ginkgo Biloba are not allowed on this study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac, arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements and/or ability for sexual function.
  • Pregnant women are excluded from this study because ArginMax may be an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ArginMax, breastfeeding should be discontinued if the mother is treated with ArginMax.
  • Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with ArginMax. Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.
  • Any planned surgery during study participation.
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00459134
CCCWFU 97106, U10CA081851
Yes
Wake Forest Cancer Center CCOP Research Base
Wake Forest Cancer Center CCOP Research Base
National Cancer Institute (NCI)
Principal Investigator: Kathryn M. Greven, MD Wake Forest Cancer Center CCOP Research Base
Wake Forest Cancer Center CCOP Research Base
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP